ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rosiglitazone Maleate And Metformin Hydrochloride, and when can generic versions of Rosiglitazone Maleate And Metformin Hydrochloride launch?
Rosiglitazone Maleate And Metformin Hydrochloride is a drug marketed by Teva and is included in one NDA.
The generic ingredient in ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; rosiglitazone maleate. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; rosiglitazone maleate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE?
- What are the global sales for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE?
- What is Average Wholesale Price for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE?
Summary for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 5 |
| Patent Applications: | 14 |
| DailyMed Link: | ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 1 |
| Daiichi Sankyo, Inc. | Phase 3 |
| Daiichi Sankyo Inc. | Phase 3 |
See all ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE clinical trials
